These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31650854)

  • 1. Efficacy of immune checkpoint inhibitors in cancer patients of different ages: a meta-analysis.
    Li J; Gu J
    Future Oncol; 2019 Nov; 15(31):3633-3646. PubMed ID: 31650854
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis.
    Nishijima TF; Muss HB; Shachar SS; Moschos SJ
    Cancer Treat Rev; 2016 Apr; 45():30-7. PubMed ID: 26946217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients' Age: A Systematic Review and Meta-Analysis.
    Ciccarese C; Iacovelli R; Bria E; Palazzo A; Maiorano BA; Mosillo C; Carbone C; Piro G; Tortora G
    J Immunother; 2020 Apr; 43(3):95-103. PubMed ID: 32080018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies.
    Roviello G; Andre F; Venturini S; Pistilli B; Curigliano G; Cristofanilli M; Rosellini P; Generali D
    Eur J Cancer; 2017 Nov; 86():257-265. PubMed ID: 29055841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
    Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: An up-to-date systematic review and meta-analysis.
    Yang M; Wang Y; Yuan M; Tao M; Kong C; Li H; Tong J; Zhu H; Yan X
    Int Immunopharmacol; 2020 Nov; 88():106876. PubMed ID: 32799113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
    Rijnders M; de Wit R; Boormans JL; Lolkema MPJ; van der Veldt AAM
    Eur Urol; 2017 Sep; 72(3):411-423. PubMed ID: 28645491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.
    Gyawali B; Hey SP; Kesselheim AS
    JAMA Netw Open; 2018 Jun; 1(2):e180416. PubMed ID: 30646078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between antibiotics use and outcome of cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Xu H; Xu X; Wang H; Ge W; Cao D
    Crit Rev Oncol Hematol; 2020 May; 149():102909. PubMed ID: 32146284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study.
    Kim H; Lee JE; Hong SH; Lee MA; Kang JH; Kim IH
    BMC Cancer; 2019 Nov; 19(1):1100. PubMed ID: 31718585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.
    Li J; Gu J
    Future Oncol; 2019 May; 15(14):1667-1678. PubMed ID: 31041879
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities.
    Xu Y; Fu Y; Zhu B; Wang J; Zhang B
    Front Immunol; 2020; 11():2023. PubMed ID: 33123120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Wang ZX; Wu HX; Xie L; Wang YN; Yang LP; He MM; Luo HY; Ding PR; Xie D; Chen G; Li YH; Wang F; Xu RH
    JAMA Netw Open; 2019 May; 2(5):e193433. PubMed ID: 31050784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.
    Elias R; Giobbie-Hurder A; McCleary NJ; Ott P; Hodi FS; Rahma O
    J Immunother Cancer; 2018 Apr; 6(1):26. PubMed ID: 29618381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
    Conforti F; Pala L; Bagnardi V; De Pas T; Martinetti M; Viale G; Gelber RD; Goldhirsch A
    Lancet Oncol; 2018 Jun; 19(6):737-746. PubMed ID: 29778737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.
    Yan Y; Kumar AB; Finnes H; Markovic SN; Park S; Dronca RS; Dong H
    Front Immunol; 2018; 9():1739. PubMed ID: 30100909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Petrelli F; Grizzi G; Ghidini M; Ghidini A; Ratti M; Panni S; Cabiddu M; Ghilardi M; Borgonovo K; Parati MC; Tomasello G; Barni S; Berruti A; Brighenti M
    J Immunother; 2020 Jan; 43(1):1-7. PubMed ID: 31574022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between patients' age and cancer immunotherapy efficacy.
    Wu Q; Wang Q; Tang X; Xu R; Zhang L; Chen X; Xue Q; Wang Z; Shi R; Wang F; Ju F; Zhang B; Zhou YL
    Oncoimmunology; 2019; 8(4):e1568810. PubMed ID: 30906662
    [No Abstract]   [Full Text] [Related]  

  • 19. Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors).
    Wu Y; Ju Q; Jia K; Yu J; Shi H; Wu H; Jiang M
    Int J Cancer; 2018 Jul; 143(1):45-51. PubMed ID: 29424425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis.
    Abdelhafeez AAM; Shohdy KS; Ibrahim W
    Cancer Invest; 2020 Mar; 38(3):150-157. PubMed ID: 31977260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.